Mediar Therapeutics has dosed the first subject in the Phase II WISPer trial of its investigational therapy, MTX-463, for IPF ...

The trial is designed to evaluate this human immunoglobulin G1 (IgG1) antibody, which targets WNT1-inducible signalling pathway protein-1 (WISP1), a matricellular protein implicated in the ...

MTX-463 is a first-in-class human IgG1 antibody developed against WNT1-inducible signaling pathway protein-1 (WISP1). WISP1 is a secreted matricellular protein shown to have a relevant role in ...

BOSTON, June 5, 2025 /PRNewswire/ -- Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first ...

For example, matricellular proteins such as CCN4 (WISP1) have been shown to modulate cellular communication and influence cell survival mechanisms. Concurrently, signalling cascades related to ...

Selected target gene Wisp-1 was either overexpressed or silenced by siRNA transfections in neonatal cardiomyocytes and effect of Tβ4 in Ang II-induced cardiac hypertrophy was evaluated. Results: ...